{"filing":{"accession_number":"0001493152-26-033360","cik":"0001716947","ticker":"ENSCW","company_name":"Ensysce Biosciences, Inc.","form":"8-K","filing_date":"2026-07-15","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226033360/form8-k.htm"},"events":[{"id":18148,"run_id":16303,"accession_number":"0001493152-26-033360","anchor_item_number":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Jeffrey Millard, Chief Operating Officer, resigned effective July 10, 2026. Item 5.02 discloses the departure of a named officer, making this a clear executive departure event. The COO role is material to the company's operations and governance.","company_name":"Ensysce Biosciences, Inc.","ticker":"ENSCW","filing_date":"2026-07-15","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":16870,"accession_number":"0001493152-26-033360","item_number":null,"item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Jeffrey Millard, Chief Operating Officer, resigned effective July 10, 2026. Item 5.02 discloses the departure of a named officer, making this a clear executive departure event. The COO role is material to the company's operations and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T20:17:09.777163+00:00","company_name":"Ensysce Biosciences, Inc.","ticker":"ENSCW","filing_date":"2026-07-15"}]}